WT1 and acute myeloid leukemia: Similar results were reported by Renneville et al., on behalf of the Acute Leukemia French Association, who studied 268 AML patients and demonstrated that patients who had WT1 mutation had a shorter 4-year OS and a higher risk of recurrence at 4 years compared to those of patients with wild-type WT1 [14].